<DOC>
	<DOCNO>NCT00281515</DOCNO>
	<brief_summary>The purpose study compare effect Paclitaxel/Carboplatin Lonafarnib Paclitaxel/Carboplatin primary treatment patient epithelial ovarian cancer .</brief_summary>
	<brief_title>Comparison Paclitaxel/Carboplatin Lonafarnib Paclitaxel/Carboplatin First-line Treatment Ovarian Cancer</brief_title>
	<detailed_description>Today standard therapy patient advance ovarian carcinoma paclitaxel carboplatin . Lonafarnib farnesyl transferase inhibitor ( FTI ) active broad spectrum tumor cell line vitro tumor xenograft nude mouse . Lonafarnib single-agent antitumor activity well enhanced activity combination taxanes number tumor cell line vivo model .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Previously untreated patient histologically confirm diagnosis cancer ovary , fallopian tube extraovarian papillary serous tumor FIGO stage IIBIV , regardless measurable nonmeasurable disease Age &gt; = 18 year ECOG performance status &lt; = 2 Lifeexpectancy least 6 month Adequate bone marrow , renal hepatic function : WBC &gt; = 3.0 x 10^9/l ; Neutrophils ( ANC ) &gt; = 1.5 x 10^9/l ; Platelets &gt; = 100 x 10^9/l ; Hemoglobin &gt; 6 mmol/l ( &gt; 10.0 g/dl ) ; Bilirubin &lt; = 1 x upper limit normal range ; Alkaline phosphatase &lt; = 2.5 x upper limit normal range ; estimate GFR &gt; = 50 ml/min accord Jelliffe CockroftGault formula Patients give sign write informed consent participate trial fully understanding implication constraint protocol Patients must geographically accessible treatment followup Time definitive surgery randomization study &lt; = 6 week Ovarian tumor low malignant potential ( borderline tumor ) Nonepithelial ovarian mixed epithelial/nonepithelial tumor ( e.g . Mixed Mullerian tumor ) Patients receive previous chemotherapy radiotherapy Prior treatment FT inhibitor Patients prior diagnosis malignancy cure surgery alone less 5 year study entry ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) Complete bowel obstruction presence symptomatic brain metastasis Concurrent severe medical problem unrelated malignancy would significantly limit full compliance study expose patient extreme risk decrease life expectancy Patients history seizure disorder central nervous system disorder ; preexist motor sensory neurologic pathology symptom &gt; NCI grade 1 History congestive heart failure ( NYHA Classification &gt; 2 , even medically control . History clinical electrocardiographically document myocardial infarction within last 6 month . History atrial ventricular arrhythmia ( &gt; = LOWN II ) Patients significant Fridericia QTc ( QTcF ) prolongation Baseline ( ie . QTcF &gt; = 470 msec ) Patients severe active infection Patients history severe hypersensitivity reaction product contain Cremophor EL ( cyclosporin vitamin K ) and/or patient know hypersensitivity compound chemically related Carboplatin Paclitaxel Women childbearing potential sexually active unwilling use medically acceptable method contraception ( oral contraceptive , diaphragm spermicide , intrauterine device , condom spermicide ) Women pregnant breast feed Administration anticancer therapy simultaneous chemotherapeutic and/or hormonal drug , radiotherapy study treatment period ( except : hormonal replacement therapy and/or steroid antiemetic ) Patients participate clinical study Dementia significantly alter mental status would prohibit understanding give informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>